Study details
Enrolling now
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelonomonocytic Leukemia
M.D. Anderson Cancer Center
NCT IDNCT06566742ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
15
Study length
about 4.7 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing if olutasidenib can help control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Olutasidenib
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
olutasidenib
Drug routes
oral (Oral Capsule)
Endpoints
Primary: Safety and adverse events (AEs)